Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Sees Significant Decrease in Short Interest

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) was the recipient of a significant drop in short interest in October. As of October 30th, there was short interest totaling 11,020,929 shares, a drop of 48.2% from the October 15th total of 21,260,757 shares. Approximately 13.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 29,799,680 shares, the short-interest ratio is presently 0.4 days.

Eyepoint Pharmaceuticals Stock Down 2.0%

Shares of EYPT stock traded down $0.01 during trading hours on Monday, reaching $0.30. 6,511,677 shares of the stock traded hands, compared to its average volume of 3,702,415. The firm has a market capitalization of $25.86 million, a PE ratio of -0.08 and a beta of 1.84. Eyepoint Pharmaceuticals has a 1-year low of $0.28 and a 1-year high of $19.11. The business has a fifty day moving average price of $2.33 and a 200 day moving average price of $10.24.

Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.14). The business had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.23 million. Eyepoint Pharmaceuticals had a negative return on equity of 168.83% and a negative net margin of 13,281.23%. Research analysts expect that Eyepoint Pharmaceuticals will post -3.46 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Commodore Capital LP acquired a new position in Eyepoint Pharmaceuticals in the first quarter valued at about $36,414,000. Aberdeen Group plc grew its position in shares of Eyepoint Pharmaceuticals by 52.0% during the 3rd quarter. Aberdeen Group plc now owns 3,053,945 shares of the company’s stock worth $9,986,000 after buying an additional 1,045,143 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Eyepoint Pharmaceuticals during the 1st quarter worth about $10,743,000. Janus Henderson Group PLC grew its position in shares of Eyepoint Pharmaceuticals by 22.6% during the 1st quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after buying an additional 663,439 shares during the period. Finally, Stempoint Capital LP increased its stake in shares of Eyepoint Pharmaceuticals by 129.1% in the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock valued at $10,451,000 after acquiring an additional 456,915 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Cantor Fitzgerald cut Eyepoint Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Monday, August 17th. Jefferies Financial Group downgraded Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a research report on Monday, October 19th. Mizuho lowered Eyepoint Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $0.50 price objective for the company. in a research note on Tuesday, October 20th. Guggenheim cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Monday, October 19th. Finally, Chardan Capital lowered Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $5.00 target price on the stock. in a research report on Tuesday, August 18th. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $21.85.

View Our Latest Analysis on EYPT

About Eyepoint Pharmaceuticals

(Get Free Report)

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.

See Also

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.